New approach aims to spare kids from steroids in transplant complication
NCT ID NCT06695507
Summary
This study tested whether a drug called ruxolitinib could be used as the first treatment for chronic graft-versus-host disease (cGVHD) in children and young adults. The goal was to see if starting with ruxolitinib could control the disease while avoiding or reducing the need for high-dose steroids, which have many side effects. The study was a small, early-phase trial that enrolled patients aged 12 to 30 with newly diagnosed, moderate-to-severe cGVHD.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
Conditions
Explore the condition pages connected to this study.